Quinine Ingestion During the Latter Stages of a 3,000-m Time Trial Fails to Improve Cycling Performance.


Journal

International journal of sport nutrition and exercise metabolism
ISSN: 1543-2742
Titre abrégé: Int J Sport Nutr Exerc Metab
Pays: United States
ID NLM: 100939812

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 03 09 2020
revised: 23 09 2020
accepted: 24 09 2020
pubmed: 2 12 2020
medline: 20 7 2021
entrez: 1 12 2020
Statut: ppublish

Résumé

The ingestion of quinine, a bitter tastant, improves short-term (30 s) cycling performance, but it is unclear whether this effect can be integrated into the last effort of a longer race. The purpose of this study was to determine whether midtrial quinine ingestion improves 3,000-m cycling time-trial (TT) performance. Following three familiarization TTs, 12 well-trained male cyclists (mean ± SD: mass = 76.6 ± 9.2 kg, maximal aerobic power = 390 ± 50 W, maximal oxygen uptake = 4.7 ± 0.6 L/min) performed four experimental 3,000-m TTs on consecutive days. This double-blind, crossover design study had four randomized and counterbalanced conditions: (a) Quinine 1 (25-ml solution, 2 mM of quinine); (b) Quinine 2, replicate of Quinine 1; (c) a 25-ml sweet-tasting no-carbohydrate solution (Placebo); and (d) 25 ml of water (Control) consumed at the 1,850-m point of the TT. The participants completed a series of perceptual scales at the start and completion of all TTs, and the power output was monitored continuously throughout all trials. The power output for the last 1,000 m for all four conditions was similar: mean ± SD: Quinine 1 = 360 ± 63 W, Quinine 2 = 367 ± 63 W, Placebo = 364 ± 64 W, and Control = 367 ± 58 W. There were also no differences in the 3,000-m TT power output between conditions. The small perceptual differences between trials at specific 150-m splits were not explained by quinine intake. Ingesting 2 mM of quinine during the last stage of a 3,000-m TT did not improve cycling performance.

Identifiants

pubmed: 33260142
doi: 10.1123/ijsnem.2020-0265
pii: ijsnem.2020-0265
doi:
pii:

Substances chimiques

Performance-Enhancing Substances 0
Solutions 0
Quinine A7V27PHC7A

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-12

Auteurs

Naroa Etxebarria (N)

University of Canberra.

Brad Clark (B)

University of Canberra.

Megan L Ross (ML)

Australian Institute of Sport.
Australian Catholic University.

Roland Goecke (R)

University of Canberra.

Ben Rattray (B)

University of Canberra.

Louise M Burke (LM)

Australian Institute of Sport.
Australian Catholic University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH